Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...

New research highlights the potential of the novel diagnostic tool iFRET to determine immunotherapy outcomes in stage 2 ...

Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...

Tax advantages offered by PEA-PME and PEA are only available to French residents. *Shares of European companies with fewer than 5,000 employees and an annual revenue of less than €1.5 billion or total ...

Oncolytic viruses are therapeutic agents used for in situ immunization in cancer immunotherapy. Unfortunately, its efficacy is particularly limited in solid tumors expressing stimulator of interferon ...

Explore how immune time-resolved Förster resonance energy transfer (iFRET) offers new insights into predicting immunotherapy ...

Report Ocean’s recent report provides an accurate and comprehensive research analysis of the “Saudi Arabia Immuno-oncology Market” with a primary focus on the present and past market conditions. The ...

Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotechnology company advancing targeted antitumor virotherapies, will host an invest ...

Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, is pleased to invite investors to a webinar on February 5 ...

Plus, news about Madrona and Ab­dera: Boehringer In­gel­heim com­bines two can­cer units: The drug­mak­er is merg­ing its can­cer vac­cine unit AMAL Ther­a­peu­tics … ...

Today, a brief rundown of news involving Merck & Co. and AstraZeneca, as well as updates from AbbVie, Stealth BioTherapeutics and Vigil Neuroscience that you may have missed. Aardvark Therapeutics ...